Instructions for Authors

The Journal of Invasive Cardiology will consider for publication suitable articles on topics pertaining to the invasive treatment of patients with cardiovascular disease.

Editorial Policies.
The statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the publisher or editors. All manuscripts submitted for publication must include the following statement signed by the senior author: “The undersigned author transfers all copyright ownership of the manuscript entitled (title of article) to HMP Communications in the event the work is published. The author warrants that the article is original, is not under consideration by another journal, and has not been previously published. I sign for and accept responsibility for releasing this material on behalf of any and all co-authors.” Include this statement in the cover letter.

Review. All articles are reviewed by two or more referees. Acceptance is based upon significance and originality. Because the review is double blind, authors’ names should not appear in the text or on the figures. Editorial revisions may be made to articles accepted for publication as an aid to clarity.

Ethics. The author is responsible for the contents submitted in the paper. Opinions expressed by authors are their own and not necessarily those of HMP Communications LLC, the editorial staff, or any member of the editorial advisory board. No claims made by authors or advertisers are guaranteed by the publisher or editors. Authors must comply with FDA guidelines, human studies guidelines and animal welfare regulations of the authors’ institution. Authors should indicate in the paper that human subjects have given informed consent and that the authors have conformed to institutional guidelines and those of the American Physiological Society.

Conflict of Interest/Disclosure. A statement acknowledging financial interest in products/companies relevant to submitted research must be disclosed to the editors when the paper is submitted. Any financial interest which may be interpreted as a conflict of interest, including stock ownership, consultancies, patent-licensing relationships, and other equity interests, must be disclosed in the cover letter. If no conflicts of interest exist, please state this.

Manuscript format. All submissions to the journal are now submitted online in a digital format through Rapid Review, a web-based, peer review system.

Rapid Review. To log onto Rapid Review, you must first have an account in the online system. Please go to www.rapidreview.com, scroll to HMP Communications and choose “author”. If you have not used the system before, please click the “new to Rapid Review” button and follow prompts to create a new account. Please note that it is not possible to create an author account without an Email address.

Submission Instructions. After logging into your account, choose “submit new MS” from your navigation bar (on the left side of the screen in Rapid Review). A submission form will appear. Please make every effort to complete all fields within the submission form, all mandatory fields are indicated with an asterisk (*). After you have completed the submission form, select “submit manuscript online” to upload the text files and digital figures that will be converted to a PDF for use by reviewers. These files must be free of author names, institutions and contact information (which has already been recorded in the submission template in Rapid Review). Figures MUST NOT include identifying patient information.

Corresponding Author/Additional authors
The corresponding author will receive all manuscript related correspondence via Email.
• NOTE: Case reports and Clinical Images are limited to 3 authors or fewer. The manuscript will not be considered until the additional authors are removed from the submission. Authors are those who participated in manuscript preparation: conception, design, research and/or writing. Others who were consulted can be mentioned in the acknowledgments section.

Title page. The title page at submission contains information helpful to the manuscript reviewer. A general disclosure statement is necessary at this stage. After acceptance, a more complete version will be requested which will contain complete information for publication purposes.
• Include the manuscript’s title, short title is optional.
• No author names or institutions should be listed on the document since the uploaded copy will be distributed to reviewers.
• Disclosure statement. The title page should contain one of the disclosure statements listed below:
  (1) The authors report no financial relationships or conflicts of interest regarding the content herein.
  (2) One or more of the authors have disclosed potential conflicts of interest regarding the content herein.
  (3) One or more of the authors has disclosed a potential conflict of interest that is not financial in nature.
**Text/Tables.**
- Use generic drug names (even if trade names are mentioned).
- When products are mentioned, list the manufacturer.
- Obtain appropriate consent for quotations of more than 50 words. Consult The Chicago Manual of Style, 14th Edition for current usage.

**Abstract.** An abstract is necessary for the review process. Depending on the type of article, it may or may not be published. For example, abstracts are not published for editorials or letters. For these types of articles, please provide a brief summary of less than 100 words. The abstracts or summaries are emailed to manuscript reviewers to help them determine if they have the expertise or interest in reviewing the article in question. For original articles and research studies, please provide a summary of less than 250 words. Abstracts can be included on the title page or the next page.

**Key words.** Please choose 2–3 words from within the submission template pulldown menu to be used in order to cross reference the subject of your manuscript with the expertise of the review board. Reviewers will be chosen based upon these selections.

**References.** References should be listed at the end of the manuscript. Numbered references must be cited, in order in the text. A complete periodical reference includes 1) authors’ names (list all authors up to four, for five or more authors, list first three followed by et al.); 2) title of article; 3) abbreviated journal name; 4) name of publisher; 5) year of publication; 6) volume number; 7) specific page numbers. For books include: 8) name of editor(s), if any; and 9) place of publication.

For example:

**Periodical.** (List all authors up to 6; for 7 or more authors, list 3 followed by et al.)

**Book.**

**Chapter in Book.** (Author is not editor of the book)

**Figure legends/copyright.**
- A descriptive legend must accompany each figure.
- All abbreviations must be identified in the figure legend.
- If a figure has been published previously, permission to reprint the figure must be obtained in writing from the copyright owner and submitted upon acceptance. Please acknowledge the source beneath the figure.

**Figures**
*(for review process)*
- Photographs may be color (RGB or CMYK) or black & white.
- For review segment, figures can be in TIFF, Powerpoint, EPS, or JPEGs.
- We can accept low resolution (72 dpi) figures for the review process only.

*(for publication)*
Please note that if an author cannot provide publication quality versions of their figures after the review process is complete, we reserve the right to transfer the publication to our online journal where low resolution figures (72 dpi) are considered acceptable.

Publication quality figures can take the following form:
- glossy photographs (color or black/white) at least 300 dpi (dots per inch).
- We require digital figures to be in JPEG or TIFF format only. Resolution must be equal to or greater than 300 dpi. We CANNOT accept figures created in PowerPoint.

**Conversion Errors.** These sometimes occur when using certain Japanese fonts that are not compatible with the system. Also, when mistakenly uploading a file that is empty or has a size of zero.

If you experience continued error messages, please send an Email to the help desk, rrhelp@cadmus.com, for help in identifying and resolving the problem.